AGP Picks
View all

Chronic pulmonary hypertension treatment market to reach $9.34 billion by 2030

11 hours ago
Chronic pulmonary hypertension treatment market to reach $9.34 billion by 2030
By AI, Created 14:30 UTC, Nov 18, 2026, AGP -

The global chronic pulmonary hypertension treatment market is projected to grow from $7.19 billion in 2025 to $7.59 billion in 2026, with North America holding the largest share. The market's expansion is being driven by rising cardiovascular disease burden, broader access to therapies and stronger demand for earlier diagnosis and long-term care.

Why it matters: - Chronic pulmonary hypertension treatment is tied to managing elevated lung blood pressure, improving heart function and supporting patient quality of life. - Market growth signals rising demand for therapies, diagnostics and care models for a condition linked to broader cardiovascular and respiratory disease trends. - The market's expansion also reflects growing use of oral therapies, imaging and specialized treatment centers.

What happened: - The chronic pulmonary hypertension treatment market rose from $7.19 billion in 2025 to a projected $7.59 billion in 2026. - The market is forecast to reach $9.34 billion by 2030. - The Business Research Company published the forecast in its Chronic Pulmonary Hypertension Treatment Global Market Report 2026. - North America held the largest market share in 2025.

The details: - The 2025-2026 growth rate is 5.6% CAGR. - The 2026-2030 forecast implies a 5.3% CAGR. - Recent growth has been driven by higher prevalence of cardiovascular and respiratory diseases, increased awareness of pulmonary hypertension and better access to oral PDE-5 inhibitors. - Growth has also been supported by more specialized treatment centers and wider use of diagnostic imaging. - Future growth is expected to come from approvals of innovative pulmonary hypertension drugs, higher investment in rare disease therapies and broader adoption of inhalation drug delivery systems. - Telemedicine for disease management and more patient-centered care models are also expected to support demand. - The report says treatment trends include targeted therapies, combination regimens, early diagnosis, ongoing monitoring, home-based oxygen and supportive therapies, and more personalized treatment approaches. - Chronic pulmonary hypertension management typically includes medications to reduce pulmonary artery pressure, oxygen therapy and diuretics. - More advanced care can include pulmonary rehabilitation, lifestyle adjustments, medical procedures and, in severe cases, surgery. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report also adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company offers a free sample of the report and the full market report.

Between the lines: - The market's pace is being shaped less by one product cycle and more by a wider shift toward chronic disease management, earlier detection and longer-term care. - The NIH projected in August 2025 that cardiovascular disease prevalence will rise 90% between 2025 and 2050, with deaths increasing from 20.5 million to 35.6 million, which points to sustained demand for related treatments. - North America's lead suggests the market rewards regions with stronger healthcare infrastructure, awareness and access to newer therapies.

What's next: - The report expects continued demand growth as new drugs, delivery systems and monitoring tools reach the market. - Wider telemedicine use and more personalized treatment approaches are likely to shape how chronic pulmonary hypertension is managed over the next several years. - Regional competition may intensify as the report tracks growth opportunities across Asia-Pacific, Europe, South America, the Middle East and Africa.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Lifestyle Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Lifestyle Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.